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Summary statement: In this interventional case series, eight patients presenting 
macular telangiectasia type 1 with macular edema were treated by intravitreal 
aflibercept. The favorable clinical response observed with this treatment is consistent 
with the profile of angiogenic factors analyzed in their aqueous humors. 
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ABSTRACT 
 
Purpose: To evaluate intravitreal aflibercept in macular telangiectasia type 1 
(MacTel1) patients and measure their ocular angiogenic profile. 
 
Methods: Eight subjects with MacTel1 refractory to bevacizumab, ranibizumab or 
laser therapy, and switched to aflibercept, were included. Best-corrected visual acuity 
(BCVA), central macular thickness (CMT), and cystic areas quantified on optical 
coherence tomography B-scans were assessed during 12 months. Perifoveal 
capillary densities were measured on OCT angiography. Aqueous humor was 
sampled from 6 patients and 8 controls undergoing cataract extraction. Growth 
factors were quantified using a multi-array immunoassay. 
 
Results: Over 12 months, patients received 6.6 ± 1.4 (range, 5-8) intravitreal 
aflibercept injections. Twelve months after switching to aflibercept, BCVA increased 
by ≥5 letters in n=5/8 patients, compared to pre-aflibercept levels. Mean BCVA 
improved from 79.6 (~20/50) to 88.0 (~20/35) ETDRS letters (P=0.042) and CMT 
decreased from 434±98 to 293±59 µm (P=0.014). Compared to controls, the profile 
of angiogenic factors in MacTel1 eyes revealed no difference in VEGF-A levels, but 
significantly higher levels of PlGF (P=0.029), soluble VEGF-receptor-1 (sFlt-1; 
P=0.013), VEGF-D (P=0.050) and Tie-2 (P=0.019). PlGF levels were inversely 
correlated to both superficial and deep capillary plexus densities on OCT 
angiography (P=0.03). 
 
Conclusion: The clinical response to aflibercept coupled to the angiogenic profile of 
MacTel1 eyes support the implication of the PlGF/Flt-1 pathway in MacTel1. 
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INTRODUCTION 
 
“Idiopathic juxtafoveal telangiectasia” is a generic term that encompasses 
different clinical entities first classified by Gass and Oyakawa in 1982,1 then by Gass 
and Blodi in 1993.1 In 2006, Yannuzzi et al.2 proposed a simplified classification 
under the term “idiopathic macular telangiectasia”, with two distinct types: type 1, 
“aneurysmal telangiectasia” and type 2, "perifoveal telangiectasia", also known as 
MacTel. These classifications are based on clinical features, as no specific molecular 
signature or pathogenic mechanisms have yet been identified.  
Idiopathic macular telangiectasia type 1 (MacTel 1) is usually unilateral and 
affects mostly men of 40-50 years of age at presentation.1 Microvascular ectasia and 
increased tortuosity of the macular capillary network are visible on fundus 
examination, may extend to the temporal side of the macula over an area of two-disc 
diameter or greater,1,2 and may be associated to peripheral vascular changes.3 
Telangiectasia frequently causes macular edema with lipid exudates of variable 
severity, and subsequent vision loss. Location, morphology and degree of leakage of 
the microvascular ectasia, as well as capillary non-perfusion are best identified on 
fluorescein angiography. 
Whether MacTel 1 is a milder, later and more central form of Coats’ disease is 
debated, since both entities associate vascular telangiectasia with aggressive 
exudation, unilateral involvement and male predominance.3,5 To confirm the 
diagnosis of MacTel 1, disorders causing secondary telangiectasia must be excluded, 
which included retinal vein occlusion, diabetic retinopathy, ocular ischemic syndrome, 
hypertensive retinopathy and more rarely posterior segment inflammation, radiation 
maculopathy, sickle-cell maculopathy or localized retinal capillary hemangioma. 
MacTel 1 is a rare disease and there is no consensus regarding treatment 
schemes. Laser photocoagulation can be performed on accessible ischemic areas 
but may also target leaky aneurysms. Intravitreal anti-vascular endothelial growth 
factor (VEGF) therapy has also been assessed, with inconstant results. Although 
bevacizumab6,7 and ranibizumab8,9 showed some efficacy in reducing macular edema 
and improving vision, three case series reported that only a minority of patients 
responded favorably to intravitreal bevacizumab.10,11,12 Recently, three groups 
reported that MacTel 1 patients may be non-responders or become refractory to 
bevacizumab13,14,15 or ranibizumab,15 including two case reports describing a 
favorable response after switching to intravitreal aflibercept.14,15 Aflibercept is a 
soluble decoy receptor that associates an immunoglobulin backbone to extracellular 
sequences of the VEGF receptors VEGFR-1 (also called Flt-1) and VEGFR-2. In 
contrast to specific anti-VEGF antibodies such as bevacizumab and ranibizumab, 
which bind to the VEGF-A isoform only, aflibercept also blocks another ligand of Flt-
1, placental growth factor (PlGF). Through its binding to Flt-1, PlGF is suspected to 
enhance vascular permeability and to amplify the effects of VEGF on pathological 
angiogenesis.16 PlGF has been implicated in the resistance to anti-VEGF treatments 
in patients with malignant tumors17,18 and various retinal diseases, including diabetic 
macular edema.19,20 Aflibercept may overcome this hurdle by neutralizing PlGF along 
with VEGF.21,22 Interestingly, in an adult rat model, the overexpression of rat PlGF did 
not induce pre-retinal neovessels, as observed when VEGF is overexpressed,23 but 
produced retinal vessel abnormalization manifested by tortuosity, dilation and 
capillary aneurysms,24 suggesting a potential role of PlGF in the pathogenesis of 
aneurysmal telangiectasia.  
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In this context, the aim of this study was to retrospectively evaluate the effect of 
intravitreal aflibercept therapy in patients with macular edema caused by MacTel 1, 
and to correlate it to the profile of angiogenic factors in aqueous humor. 
 
METHODS 
 
Subjects 
 
This retrospective interventional case series involving eight human subjects and 
eight healthy controls adhered to the tenets of the Declaration of Helsinki. The 
protocol was approved by the local Ethics Committee of the Swiss Department of 
Health on research involving human subjects (CER-VD N°95/15 and 340/15) and by 
an Institutional Review Board from Western Institutional Review Board (Puyallup, 
Washington). All patients signed an informed consent form before aqueous humor 
sampling. Six consecutive patients followed from December 2013 to July 2015at 
Jules-Gonin Eye Hospital (Lausanne, Switzerland), and two consecutive patients 
followed at the Vitreous, Retina, Macula Consultants of New York (New York, USA) 
were included in this study. Inclusion criteria were: 1) macular edema due to 
idiopathic MacTel 1 without medical or ophthalmological history suggesting 
secondary macular telangiectasia, and 2) persistence of macular edema following a 
well-conducted treatment by retina specialists with intravitreal bevacizumab (Avastin; 
Genentech, Inc., South San Francisco, CA, USA), ranibizumab (Lucentis; Novartis 
Pharma AG, Basel, Switzerland and Genentech, Inc., South San Francisco, CA, 
USA) and/or laser photocoagulation, justifying a treatment switch to intravitreal 
aflibercept (Eylea; Bayer, Leverkusen, Germany). 
Eight sex- and age-matched patients undergoing cataract surgery and having no 
history of diabetes or retinal disease were included during the same period as control 
subjects for aqueous humor sampling. 
  
Patient treatment and follow-up 
 
Following two initial monthly loading doses, patients received intravitreal 
aflibercept on a pro re nata (as needed) regimen. Decision for re-injection was made 
by two retina specialists (RFS or FBC), and re-injections were performed at intervals 
of 4 weeks or more. They were indicated in case of persistent or recurrent macular 
edema manifesting by intraretinal cysts and/or subretinal fluid. 
At all visits, best-corrected visual acuity was measured using an Early Treatment 
Diabetic Retinopathy Study (EDTRS) chart, and serial Spectral-Domain Optical 
Coherence Tomography (SD-OCT) images on Spectralis (Heidelberg Engineering, 
Heidelberg, Germany) were obtained. Confocal fluorescein and indocyanine green 
angiography on Spectralis had been performed in all cases at presentation for the 
diagnosis of MacTel 1 and were repeated at the discretion of the treating retina 
specialist. Optical coherence tomography angiography (OCTA) images were 
acquired using the Angiovue RTx 100, based on the AngioVue Imaging System 
(Optovue, Inc., Freemont, CA). 
Clinical charts were retrospectively reviewed, and data were recorded at baseline 
(corresponding to the last visit before the first intravitreal aflibercept injection) and 
one, three, six and twelve months after baseline. 
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Spectral-domain optical coherence tomography imaging and quantification of 
intraretinal cysts area 
 
At each time point, high-quality 30° horizontal single B-scans SD-OCT and 
20°20° 97-section horizontal grids were acquired using the follow-up mode on 
Spectralis. The central macular thickness (CMT) was automatically measured in the 
central subfield of an ETDRS grid on the built-in software. For graphical purposes, 
the boundaries of the cystoid edema regions were outlined with a red contour and 
superimposed over the original SD-OCT images, using a custom semi-automated 
algorithm on Matlab (Version R2015b, Mathworks, Natick, MA, USA) detailed in the 
supplemental Figure.  
 
Optical coherence tomography angiography imaging and macular capillary 
density 
 
The optical coherence tomography angiography Angiovue RTx 100 instrument 
was used to obtain amplitude decorrelation angiography images. This instrument has 
an A-scan rate of 70,000 scans per second, using a light source centered on 840 nm 
and a bandwidth of 50 nm. Each OCTA volume contains 304 x 304 A-scans with two 
consecutive B-scans captured at each fixed position before proceeding to the next 
sampling location. Split-spectrum amplitude-decorrelation angiography was used to 
extract the OCTA information. Each OCTA volume is acquired in 3 seconds and two 
orthogonal OCTA volumes are acquired in order to perform motion correction. 
Angiography information displayed is the average of the decorrelation values when 
viewed perpendicularly through the thickness being evaluated. 
In order to obtain comparable 33-mm OCTA scans between subjects, volumes 
were automatically segmented by the built-in software to provide images of the 
superficial plexus (3 µm below the inner limiting membrane to 16 µm below the outer 
border of the inner plexiform layer) and deep plexus (16-69 µm below the outer 
border of the inner plexiform layer). The correct segmentation for each patient was 
controlled before reporting the capillary densities calculated using the AngioVue 
software.  
 
Aqueous humor sampling 
 
At the time of an aflibercept intravitreal injection indicated for macular edema, 50-
150 µL of aqueous humor were sampled by anterior chamber tap before the injection, 
using a 30-Gauge needle and a 1-mL syringe, and immediately frozen at -80°C. 
Before aqueous humor sampling, a time lapse of at least 7 weeks from the previous 
anti-VEGF injection (ranibizumab, bevacizumab or aflibercept) was observed in all 
patients. Given that pharmacological observations25,26,27 and mathematical models28 
have estimated the vitreous elimination half-life (t1/2) of ranibizumab, bevacizumab 
and aflibercept to be respectively t1/2=3.2-7.2 days, t1/2= 4.9-5.6 days, and t1/2=4.6-4.8 
days,25-28 aqueous sampling was performed when no residual anti-VEGF drug 
remained in the vitreous, after a clearance time ≥ 7t1/2. In the control group, the 
anterior chamber tap was performed at the beginning of cataract surgery before any 
fluid was injected into the anterior chamber. 
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Angiogenic factor levels in aqueous humors 
 
Aqueous humor levels of soluble VEGFR-1 (sFlt-1), PlGF, the tyrosine kinase 
receptor Tie-2 with immunoglobulin-2 and EGF-like domains (Tie-2), VEGF-A165, 
VEGF-C, VEGF-D, and basic Fibroblast Growth Factor (bFGF) were measured, on 
the same plate, using a multi-array high-sensitive immunoassay (V-PLex 
Angiogenesis Panel 1 Kit; Meso Scale Discovery, Rockville, MD, USA). This 
standardized kit was used according to the manufacturer’s instructions. Standard 
curves for each angiogenic factor were generated with the provided calibration kit 
and the samples were assayed in duplicate, without dilution. Data acquisition and 
analysis were performed with the Meso Scale reader (MSD Quickplex SQ-120, Meso 
Scale Diagnostics, Rockville, MD, USA) and its dedicated software (Discovery 
Benchmark version 4.0.12). Detection thresholds for all angiogenic factors were set 
between 1 and 20 pg/mL and coefficients of variation were inferior to 10%. 
 
Statistical analysis 
 
Results were expressed as mean ± standard deviation (SD). Biological and 
clinical analyses were carried out on GraphPad Prism 5 (GraphPad Software Inc., La 
Jolla, CA, USA). The nonparametric Mann-Whitney U-test and Wilcoxon paired test 
were used to compare data, when applicable. Spearman correlation was used to 
evaluate relationships between angiogenic factors levels and clinical parameters. A 
two-tailed P-value<0.05 was considered statistically significant. 
 
 
 
RESULTS 
 
Patient characteristics 
 
Eight patients with MacTel 1, seven male and one female, with a mean age of 
63.0±10.3 years (range, 45-74 years) were included in this study. Clinical 
characteristics, previous treatments, and number of intravitreal aflibercept injections 
are reported in Table 1. All patients had been previously treated with extra-macular 
and/or macular laser photocoagulation, combined with intravitreal anti-VEGF therapy 
in 7 patients. Four patients had received bevacizumab, two patients had received 
ranibizumab, and one patient had received sequentially bevacizumab, ranibizumab 
and dexamethasone implant. Following an optimal treatment regimen with these 
therapies the patients had a mean central macular thickness of 434 ± 98 µm. Over 
the 12-month study period, they received 6.6 ± 1.4 intravitreal aflibercept injections 
(range, 5-8). 
 
Effect of intravitreal aflibercept therapy 
 
A clinical illustration of a patient refractory to bevacizumab therapy and 
responsive to aflibercept therapy is provided in Figure 1 (Case 4). Figure 2 shows the 
baseline and 12-month SD-OCT B-scans and corresponding thickness maps from 
the eight patients included in this study, demonstrating the clinical response to 
aflibercept treatment. 
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The anatomical and visual outcomes of intravitreal aflibercept therapy by 12 
months are summarized in Table 2. The CMT decreased in all patients, with a 
significant reduction from 434 ± 98 µm to 293 ± 59 µm (P=0.014). The best-corrected 
visual acuity improved in 7 out of 8 patients with a mean significant improvement 
from 79.6 ± 16.3 (~20/52) to 88.0 ± 11.2 (~20/35) ETDRS letters (P =0.042). There 
was an improvement by 5 or more ETDRS letters in 5 out of 8 patients. Both 
anatomical and visual parameters improved progressively over time, as illustrated in 
Figure 3. After one intravitreal aflibercept injection, a reduction in central macular 
thickness was observed in all patients, with a significant reduction as compared to 
baseline (308.6 ± 32.9 µm, P=0.016), that was maintained over the 12-month follow-
up. By month 6, visual acuity levels were significantly improved (88.0 ± 11.3 letters 
(~20/35), P=0.02), which was maintained at the 12-month time point. 
 
Angiogenic factor levels in aqueous humor 
 
The eight individuals selected for the control group of aqueous humor analysis 
were male with a mean age of 68 ± 12 years old (range, 50-85), not significantly 
different from the six subjects with MacTel 1 from whom aqueous humor was 
sampled (Cases 1 to 6, mean age: 61 ± 11 years, P=0.40).  
The profiles of angiogenic factors in the aqueous humor of patients with MacTel 
1, compared to healthy controls, are represented in Figure 4. There was no 
difference in VEGF-A levels (1.3, P=0.95), but significantly higher levels of sFlt-1 
(4.3, P=0.013), PlGF (2.2, P=0.029), as well as Tie-2 (3.7, P=0.019) and VEGF-D 
(6.8, P=0.049). VEGF-C and bFGF levels were higher without reaching statistical 
significance. Mean aqueous levels of angiogenic factors in affected and control 
subjects are reported in the Table 3. 
 
Correlations between imaging and biological parameters 
 
OCTA scans were analyzed to determine the perifoveal capillary densities in the 
superficial and deep capillary plexuses. Figure 5 provides an illustration of multimodal 
imaging in one patient (Case 1), with OCTA of the superficial and deep capillary 
plexuses, and the corresponding capillary density maps. 
An exhaustive account of the functional and anatomical parameters, as well as 
aqueous levels of angiogenic factors is given in the Supplemental Table 1. When 
exploring possible correlations between these parameters (Supplemental Table 2), 
we found a significant, inverse correlation between the perifoveal capillary density of 
both superficial and deep capillary plexuses on OCTA, and aqueous levels of PlGF 
(P=0.03, r=-0.89).  
 
DISCUSSION 
 
In this case series of 8 patients with MacTel 1, treatment by intravitreal 
aflibercept, that blocks both VEGF-A and PlGF, showed significant anatomical and 
functional effects on macular edema. Anatomical improvement was observed after 
one intravitreal injection of aflibercept in all cases, including those incompletely 
responsive to other anti-VEGF therapies that do not inhibit the PlGF-mediated Flt1 
pathway. These results are supported by measurements of higher levels of PlGF, but 
not VEGF-A, in the aqueous humor of patients with MacTel 1 compared to healthy 
controls. 
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There are to date two case reports on the effects of intravitreal aflibercept in 
MacTel 1. Shibeeb et al.14 described the complete resolution of macular edema and 
visual improvement after 4 aflibercept injections in one MacTel 1 case refractory to 3 
monthly bevacizumab injections, and to laser photocoagulation. Recently, Kovach et 
al.15 reported the beneficial effect over 3 years of aflibercept therapy on macular 
edema secondary to MacTel1 in one patient previously non-responding to 6 monthly 
bevacizumab, 7 monthly ranibizumab, and 3 triamcinolone acetonide injections. 
These findings are consistent with our observations. Before the intravitreal 
formulation of aflibercept became available for retina specialists, several investigators 
had evaluated the intravitreal anti-VEGF antibodies bevacizumab and ranibizumab in 
type 1- and type 2- idiopathic macular telangiectasia, with limited outcomes. 
Noticeably, the exact role of VEGF in the development of primary telangiectasia is 
not clear, and intra-ocular VEGF levels in type 1 or type 2 idiopathic macular 
telangiectasia had not been reported before the present study. Two case reports 
have suggested a favorable effect of intravitreal bevacizumab on MacTel 1,6,7 but 
these observations were not confirmed by three small case series. Matsumoto and 
Yuzawa reported 4 patients with MacTel 1 who received 3 to 4 intravitreal 
bevacizumab injections, over a 6-month period. The microaneurysms regressed in 
one of the four eyes, but visual acuity did not improve in any of the patients.10 
Takayama et al. reported five cases with MacTel 1, treated with 2 to 3 intravitreal 
bevacizumab over one year, among which only one eye showed a reduction in 
macular edema and an improvement in visual acuity.11 Finally, Moon et al. also 
reported seven patients with MacTel 1 treated with intravitreal bevacizumab during 4 
months. Although a significant decrease in CMT was observed on SD-OCT, there 
was no significant improvement in visual acuity.12 In idiopathic macular telangiectasia 
type 2 (or MacTel), several studies have demonstrated that anti-VEGF therapy by 
bevacizumab or ranibizumab did not improve the visual acuity on the long-term, 
although it reduced leakage from telangiectasia in the non-proliferative form of the 
disease.29-33  
In Coats’ disease, which belongs to the same spectrum of microvascular 
disorders as MacTel 1,5 anti-VEGF agents have become an effective adjunct therapy 
in the management of retinal exudation.34,35,36 Their clinical efficacy is supported by 
elevated VEGF levels in the subretinal fluid37 and aqueous humor38 of eyes with 
Coats’ disease, as compared to control eyes from age-matched patients with 
rhegmatogenous retinal detachment or congenital cataract, respectively. Moreover, 
immune-localization of VEGF and VEGF-receptors were performed on enucleated 
eyes with advanced Coats’ disease,39 and showed that VEGF-A was expressed in 
vascular endothelial cells and macrophages, and that VEGF-R2 (mediating 
angiogenesis after VEGFA stimulation) was localized in endothelial cells lining 
abnormal vessels, but not VEGF-R1/Flt1 (mediating vascular permeabilization and 
cell migration, and possibly modulating VEGF-R2 activation16) nor VEGF-R3 
(signaling lymphangiogenesis). In contrast to MacTel 1, these data indicate that the 
VEGF-A-mediated VEGF-R2 pathway is specifically activated in Coats’ disease, 
supporting the better response to bevacizumab or ranibizumab in Coats’ disease 
than in MacTel 1. Similarly, PlGF was not detected in 18 aqueous humors from 
patients with wet age-related macular degeneration (AMD),40  supporting the efficacy 
of bevacizumab in wet AMD. 
In contrast, the higher efficacy of aflibercept over specific anti-VEGF antibodies in 
patients with MacTel 1, previously reported14,15 and observed in our case series, 
suggest that the PlGF-mediated VEGF-R1/Flt1-pathway is involved in the 
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pathophysiology of MacTel 1, leading to vascular abnormalities such as 
telangiectasias, microaneurysms and vascular tortuosity. This assumption is 
supported by the increased aqueous humor levels of PlGF in MacTel 1 eyes as 
compared to age-matched healthy controls. 
In the healthy retina, the level of PlGF expression in endothelial cells is 100-fold 
higher than the expression of VEGF,41 and VEGF-R1/Flt-1 is the major VEGF 
receptor expressed in endothelial cells and in pericytes.42 In our previous 
experimental study, long-lasting over-expression of rat PlGF in the rat eye induced 
vascular tortuosity and aneurysmal dilation of retinal capillaries, without 
neovascularization.24 Similarly, overactivation of the PlGF-VEGFR-1/Flt-1 pathway 
induced a substantial increase in the branching, tortuosity, and leakiness of vessels 
in different organs of rodent models including skin,43 and branches of the aorta.44 
Moreover, in MacTel 1 patients, macular edema results from vascular 
abnormalization and leakage without true neovascularization,3 which is consistent 
with the non-elevated VEGF-A levels measured in their aqueous humor. Along with 
the telangiectasia, variably extended, focal areas of decreased perfusion are a 
classical finding in MacTel 1.2,3 This observation was recently confirmed using 
OCTA.45 Under these minimally ischemic conditions, PlGF could be a major player in 
the development of abnormal vessels, as shown here by the positive correlation 
between aqueous PlGF levels and the extension of capillary loss in the superficial 
and deep capillary plexus on optical coherence tomography angiography. In addition, 
higher levels of the soluble VEGFR-1 (sFlt-1), which binds with a high affinity to both 
PlGF and VEGF-A,46 were measured in MacTel 1 eyes, as compared to control eyes, 
indicating a possible counter-regulatory increase in sFlt-1 in response to high PlGF 
levels. Levels of the soluble form of the angiopoietin receptor Tie-2 were also higher 
in MacTel 1 eyes. Interestingly, the Flt-1/VEGF signaling,47 and the Ang-Tie2 
signaling are involved in the loss of pericytes,48  which could contribute to 
microaneurysm formation.42 
The role of VEGF-A has also been questioned in other aneurysmal disorders 
affecting smaller or larger vessels. For instance, in abdominal aortic aneurysm, no 
significant difference in VEGF-A expression was demonstrated between the aortic 
wall of pathologic specimens and normal aortas from organ donors, but the 
expression of VEGF-C and VEGF-D was significantly increased in the abluminal 
layer of the aorta.49 Moreover, the difference in angiogenic factor levels could affect 
the response to treatments, as in colo-rectal cancer where high circulating levels of 
VEGF-D are suspected to reduce the efficacy of bevacizumab therapy.50 
Remarkably, VEGF-D, but not VEGF-A levels, were significantly increased in the 
aqueous humor of MacTel 1 patients, suggesting it may also contribute to abnormal 
retinal vessel dilation and to resistance to intravitreal bevacizumab. 
A similar approach has been recently proposed by Noma and collaborators, who 
investigated the aqueous profile of angiogenic factors in retinal vein occlusions51,52 
and found increased levels of VEGF-A, PlGF, and sFlt-1 compared to control eyes. 
Noticeably, microvascular remodeling causing secondary telangiectasia occur in 
retinal vein occlusions that may be PlGF-mediated. In contrast to MacTel 1, macular 
edema caused by vein occlusions respond favorably to bevacizumab,53,54 
ranibizumab55,56 or aflibercept57 therapy, which may be linked to the relative elevation 
of both VEGF-A and PlGF in the ocular media of these patients. 
The present study has several limitations, including the small sample size, due to 
the low prevalence of MacTel 1. The only way to increase the statistical power and 
significance would be to get more samples from Mactel 1 patients, which requires an 
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inordinate amount of time and would hinder reporting of a worthwhile treatment. In 
addition, the follow-up duration was limited to 12 months, due to the recent 
availability of aflibercept, and we did not report the follow-up on OCTA for possible 
microvascular changes with aflibercept therapy, also due to the recent availability of 
this imaging technology. Also, other angiogenic or inflammatory factors could have 
been assessed with the multi-array immunoassay experiment, but we focused on the 
major angiogenic factors and receptors of the VEGF family presumed to be involved 
in retinal vascular diseases.  
In conclusion, we found that MacTel 1 patients with macular edema have higher 
aqueous humor levels of PlGF, but not VEGF-A, as compared to sex and age-
matched controls. Aflibercept, a neutralizer of both VEGF-A and PlGF, exerts 
beneficial anatomical and functional effects in these patients who did not show a 
good response to other therapy than aflibercept. To elucidate this effect and the 
observed angiogenic profile a hypothesis suggesting PlGF-VEGFR-1(Flt-1) pathway 
activation in Mactel 1 was generated, that best explained the data. These results 
should be confirmed by larger prospective studies. 
 
 
  
 12 
REFERENCES  
 
1 Gass JD, Oyakawa RT. Idiopathic juxtafoveolar retinal telangiectasis. Arch 
Ophthalmol. 1982;100(5):769-780 
2 Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis. Update of 
classification and follow-up study. Ophthalmology. 1993;100(10):1536-1546 
3 Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B. Idiopathic 
macular telangiectasia. Arch Ophthalmol. 2006;124(4):450-460  
4  Smithen LM, Brown GC, Brucker AJ, Yannuzzi LA, Klais CM, Spaide RF. Coats' 
disease diagnosed in adulthood. Ophthalmology. 2005 ;112(6):1072-1078 
5 Cahill M, O'Keefe M, Acheson R, Mulvihill A, Wallace D, Mooney D. 
Classification of the spectrum of Coats' disease as subtypes of idiopathic retinal 
telangiectasis with exudation. Acta Ophthalmol Scand. 2001;79(6):596-602. 
6 Gamulescu M-A, Walter A, Sachs H, Helbig H. Bevacizumab in the treatment of 
idiopathic macular telangiectasia. Graefes Arch. Clin. Exp. Ophthalmol. 
2008;246(8):1189-1193. 
7 Koay CL, Chew FLM, Visvaraja S. Bevacizumab and type 1 idiopathic macular 
telangiectasia. Eye (Lond) 2011;25(12):1663-1665; author reply 1665. 
8 Ciarnella A, Verrilli S, Fenicia V, et al. Intravitreal ranibizumab and laser 
photocoagulation in the management of idiopathic juxtafoveolar retinal telangiectasia 
type 1: a case report. Case Rep Ophthalmol. 2012;3(3):298-303. 
9 Rouvas A, Malamos P, Douvali M, Ntouraki A, Markomichelakis NN. Twelve months 
of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic 
parafoveal telangiectasia. Clin Ophthalmol. 2013;7:1357-1362 
10 Matsumoto Y, Yuzawa M. Intravitreal bevacizumab therapy for idiopathic macular 
telangiectasia. Jpn. J. Ophthalmol. 2010;54(4):320-324. 
11 Takayama K, Ooto S, Tamura H, et al. Intravitreal bevacizumab for type 1 
idiopathic macular telangiectasia. Eye (Lond) 2010;24(9):1492-1497. 
12 Moon BG, Kim YJ, Yoon YH, Lee JY. Use of intravitreal bevacizumab injections to 
treat type 1 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol. 
2012;250(11):1697-1699. 
13 Loutfi M, Papathomas T, Kamal A. Macular oedema related to idiopathic macular 
telangiectasia type 1 treated with dexamethasone intravitreal implant (ozurdex). Case 
Rep Ophthalmol Med. 2014;2014:231913 
14 Shibeeb O, Vaze A, Gillies M, Gray T. Macular oedema in idiopathic macular 
telangiectasia type 1 responsive to aflibercept but not bevacizumab. Case Rep 
Ophthalmol Med. 2014;2014:219792.1 
15 Kovach JL, Hess H, Rosenfeld PJ. Macular Telangiectasia Type 1 Managed With 
Long-Term Aflibercept Therapy. Ophthalmic Surg Lasers Imaging Retina. 
2016;47(6):593-595. 
16 Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra- and 
intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med. 
2003;9(7):936-943. 
 13 
17 Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-
inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007;131(3):463-
475. 
18 Fan F, Samuel S, Gaur P, et al. Chronic exposure of colorectal cancer cells to 
bevacizumab promotes compensatory pathways that mediate tumour cell migration. 
Br J Cancer. 2011;104(8):1270-1277 
19 Miyamoto N, de Kozak Y, Jeanny JC, et al. Placental growth factor-1 and epithelial 
haemato-retinal barrier breakdown: potential implication in the pathogenesis of 
diabetic retinopathy. Diabetologia. 2007;50(2):461-470 
20 Rahimy E, Shahlaee A, Khan MA, et al. Conversion to Aflibercept After Prior Anti-
VEGF Therapy for Persistent Diabetic Macular Edema. Am J Ophthalmol. 
2016;164:118-127.e2. 
21 Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular 
endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab 
and bevacizumab. Angiogenesis 2012;15(2):171-185. 
22 Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and 
PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008;8(12):942-956. 
23 Okamoto N, Tobe T, Hackett SF, et al.  Transgenic mice with increased expression 
of vascular endothelial growth factor in the retina: a new model of intraretinal and 
subretinal neovascularization. Am J Pathol. 1997; 151(1): 281–291. 
24 Kowalczuk L, Touchard E, Omri S, et al. Placental growth factor contributes to 
micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic 
retinopathy. PLoS One. 2011;6(3):e17462 
25 Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of 
ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 
2012;154(4):682-686 
26 Moisseiev E, Waisbourd M, Ben-Artsi E, et al. Pharmacokinetics of bevacizumab 
after topical and intravitreal administration in human eyes. Graefes Arch Clin Exp 
Ophthalmol. 2014;252(2):331-337 
27 Christoforidis JB, Williams MM, Kothandaraman S, Kumar K, Epitropoulos FJ, 
Knopp MV. Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit 
model using PET/CT. Curr. Eye Res. 2012;37(12):1171-1174 
28 Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing 
every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and 
aflibercept (vascular endothelial growth factor Trap-eye). Retina. 2012;32(3):434-457 
29 Charbel Issa P, Scholl HP, Holz FG. Short-term effects of intravitreal bevacizumab 
in type II idiopathic macular telangiectasia. Retin Cases Brief Rep. 2007 
Fall;1(4):189-191 
30 Charbel Issa P, Finger RP, Kruse K, Baumüller S, Scholl HP, Holz FG. Monthly 
ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month 
prospective study. Am J Ophthalmol. 2011;151(5):876-886 
31 Do DV, Bressler SB, Cassard SD, et al. Ranibizumab for macular telangiectasia 
type 2 in the absence of subretinal neovascularization. Retina. 2014;34(10):2063-
2071. 
 14 
32 Kupitz EH, Heeren TFC, Holz FG, Charbel Issa P. Poor long-term outcome of anti-
vascular endothelial growth factor therapy in nonproliferative macular telangiectasia 
type 2. Retina. 2015;35(12):2619-2626. 
33 Roller AB, Folk JC, Patel NM, et al. Intravitreal bevacizumab for treatment of 
proliferative and nonproliferative type 2 idiopathic macular telangiectasia. Retina. 
2011;31(9):1848-1855. 
34 Sigler EJ, Randolph JC, Calzada JI, Wilson MW, Haik BG. Current management of 
Coats disease. Surv Ophthalmol 2014;59(1):30-46. 
35 Gaillard M-C, Mataftsi A, Balmer A, Houghton S, Munier FL. ranibizumab in the 
management of advanced Coats disease Stages 3B and 4: long-term outcomes. 
Retina. 2014;34(11):2275-2281. 
36 Daruich A, Matet A, Tran HV, Gaillard M-C, Munier FL. Extramacular fibrosis in 
Coats’ disease. Retina. March 2016. 
37 Zhang H, Liu ZL. Increased nitric oxide and vascular endothelial growth factor 
levels in the aqueous humor of patients with coats' disease. Ocul Pharmacol Ther. 
2012;28(4):397-401 
38 He YG, Wang H, Zhao B, Lee J, Bahl D, McCluskey J. Elevated vascular 
endothelial growth factor level in Coats' disease and possible therapeutic role of 
bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2010;248(10):1519-152 
39 Kase S, Rao NA, Yoshikawa H, et al. Expression of vascular endothelial growth 
factor in eyes with Coats' disease. Invest Ophthalmol Vis Sci. 2013;54(1):57-62 
 
40 Muether PS, Neuhann I, Buhl C, Hermann MM, Kirchhof B, Fauser S. Intraocular 
growth factors and cytokines in patients with dry and neovascular age-related 
macular degeneration. Retina. 2013;33(9):1809-1814. 
41 Yonekura H, Sakurai S, Liu X, et al. Placenta growth factor and vascular 
endothelial growth factor B and C expression in microvascular endothelial cells and 
pericytes. Implication in autocrine and paracrine regulation of angiogenesis. J Biol 
Chem. 1999;274(49):35172-35178 
42 Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular 
endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 
2003;22(1):1-29. Review. 
43 Odorisio T, Schietroma C, Zaccaria ML, et al. Mice overexpressing placenta growth 
factor exhibit increased vascularization and vessel permeability. J Cell Sci. 
2002;115(Pt 12):2559-2567. 
44 Kearney JB, Kappas NC, Ellerstrom C, DiPaola FW, Bautch VL. The VEGF 
receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and 
branching morphogenesis. Blood. 2004;103(12):4527-4535. 
45 Matet A, Daruich A, Dirani A, et al. Macular telangiectasia type 1: capillary density 
and microvascular abnormalities assessed by optical coherence tomography 
angiography. Am J Ophthalmol. 2016 in press 
46 Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual 
regulator for angiogenesis. Angiogenesis. 2006;9(4):225-230; discussion 231. 
 15 
47 Cao R, Xue Y, Hedlund EM, et al. VEGFR1-mediated pericyte ablation links VEGF 
and PLGF to cancer-associated retinopathy. Proc Natl Acad Sci U S A. 
2010;107(2):856-861. 
48 Cai J, Ruan Q, Chen ZJ, Han S. Connection of pericyte-angiopoietin-Tie-2 system 
in diabetic retinopathy: friend or foe? Future Med Chem. 2012;4(17):2163-2176 
49 Wolanska M, Bankowska-Guszczyn E, Sobolewski K, Kowalewski R. Expression 
of VEGFs and its receptors in abdominal aortic aneurysm. Int Angiol. 2015; 
34(6):520-528. 
50 Weickhardt AJ, Williams DS, Lee CK, et al. Vascular endothelial growth factor D 
expression is a potential biomarker of bevacizumab benefit in colorectal cancer. Br J 
Cancer. 2015; 113(1):37-45 
51 Noma H, Mimura T, Yasuda K, Shimura M. Role of soluble vascular endothelial 
growth factor receptors-1 and -2, their ligands, and other factors in branch retinal vein 
occlusion with macular edema. Invest Ophthalmol Vis Sci. 2014;55(6):3878-3885. 
52 Noma H, Mimura T, Yasuda K, Shimura M. Role of soluble vascular endothelial 
growth factor receptor signaling and other factors or cytokines in central retinal vein 
occlusion with macular edema. Invest Ophthalmol Vis Sci. 2015;56(2):1122-1128. 
53 Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal 
vein occlusion. Am J Ophthalmol. 2007;144(6):864-871. 
54 Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal bevacizumab injections for 
treatment of central retinal vein occlusion: six-month results of a prospective trial. 
Retina. 2007;27(8):1004-1012. 
55 Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema 
following central retinal vein occlusion: six-month primary end point results of a phase 
III study. Ophthalmology. 2010;117(6):1124-1133.e1. 
56 Kinge B, Stordahl PB, Forsaa V, et al. Efficacy of ranibizumab in patients with 
macular edema secondary to central retinal vein occlusion: results from the sham-
controlled ROCC study. Am J Ophthalmol. 2010;150(3):310-314 
57 Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular 
edema due to central retinal vein occlusion: two-year results from the COPERNICUS 
study. Ophthalmology. 2014;121(7):1414-1420.e1. 
 
  
 16 
TABLES AND FIGURES 
 
 
 
   Treatments Received Before Aflibercept   
Eye # Age, 
years 
Sex 
 
Laser 
photocoagulation 
Intravitreal injections 
(Number) 
Central macular 
thickness before 
aflibercept 
initiation, µm 
Intravitreal 
aflibercept 
injections over 
12 months 
1 71 M Macular + 
Extramacular 
Ranibizumab (8) 528 8 
2 68 M Macular + 
Extramacular 
Ranibizumab (1) 394 7 
3 56 M Macular + 
Extramacular 
Bevacizumab (10) 348 5 
4 45 M Macular Bevacizumab (6) 396 5 
5 54 M Macular 
(subthreshold) + 
Extramacular 
None 595 7 
6 74 M Macular + 
Extramacular 
Bevacizumab (6) 393 8 
7 72 F Macular + 
Photodynamic 
therapy 
Bevacizumab (2) + 
Ranibizumab (2) + 
Dexamethasone (1) 
508 8 
8 64 M Macular Bevacizumab (5) 312 5 
 
Table 1. Clinical characteristics and treatment history of eight patients with 
macular telangiectasia type1, refractory to previous therapies and treated by 
intravitreal aflibercept during a 12-month period. 
 
 
 
Table 2. Functional and anatomical outcome of intravitreal aflibercept in eight 
patients with macular telangiectasia type 1. Baseline values were recorded one 
month after the last administration of the previous intravitreal or laser treatment. 
ETDRS, Early Treatment Diabetic Retinopathy Study; SD, Standard Deviation; SD-
OCT, spectral-domain Optical Coherence Tomography 
a Wilcoxon signed rank test 
 
 
  
Mean ± SD Baseline 12 months P-value
a
 
Best-corrected visual acuity, 
ETDRS letter score 
(Snellen) 
79.6 ± 16.3 
(~20/52) 
88.0 ± 11.2 
(~20/35) 
.042 
 
Central macular thickness, µm 
 
434.3 ± 98.0 
 
292.5 ± 58.6 .014 
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Concentrations  
Mean ± SD 
Controls 
(pg/mL) 
MacTel 1 
(pg/mL) 
Fold change 
MacTel 1 vs Controls 
P value
a
 
sFlt1 173.9 ± 71.17 755.9 ± 1050 × 4.3 .013 
PIGF     2.1 ± 1.06     4.5 ± 2.62
 
× 2.2 .029 
Tie-2     5.0 ± 3.73   18.7 ± 9.02 × 3.7 .019 
VEGF-A 140.9 ± 44.01 187.3 ± 209.7 × 1.3 .950 
VEGF-C     5.3 ± 5.63   13.2 ± 6.55 × 2.4 .110 
VEGF-D     0.4 ± 0.40     6.8 ± 7.14 × 17.4 .049 
bFGF     0.9 ± 0.65     3.9 ± 4.16 × 4.3 .060 
 
Table 3. Angiogenic factors levels in aqueous humors of healthy control 
subjects and patients with macular telangiectasia type 1, determined on a 
multi-array immunoassay. bFGF, basic Fibroblast Growth Factor; ETDRS, Early 
Treatment Diabetic Retinopathy Study; MacTel 1, Macular telangiectasia type 1; 
PlGF, Placental Growth Factor; SD, Standard Deviation; sFlt1, soluble VEGF 
receptor 1; Tie-2, Tyrosine kinase with immunoglobulin-2 and EGF-like domains; 
VEGF, Vascular Endothelial Growth Factor 
a Mann-Whitney test 
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Figure 1. Differential effects of bevacizumab and aflibercept on macular edema 
in a 45-year-old patient with macular telangiectasia type 1 (Case 4). (A) Color 
fundus photograph showing capillary dilations and hard exudates. (B-C) Fluorescein 
angiography frames at 47 seconds (B) and 3.5 minutes (C) after dye injection 
showing leaky microaneurysms. (D-G) Horizontal optical coherence tomography B-
scans of the macula acquired at different time points: at initial presentation (D), one 
month after the last of six intravitreal bevacizumab injections administered over 7 
months (E), one (F) and twelve (G) months after the first intravitreal aflibercept 
injection. The patient received five intravitreal aflibercept injections over the 12-month 
follow-up. On each optical coherence tomography image, intraretinal cystoid cavities 
were outlined by a red line using a semi-automated algorithm. 
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Figure 2. Clinical effect of aflibercept intravitreal therapy over 12 months in 
eight patients with macular telangiectasia type 1. (A) Optical coherence 
tomography thickness maps and horizontal b-scans through the fovea at baseline 
and (B) 12 months after initiation of intravitreal aflibercept. Central macular thickness 
and the area of cystoid spaces on the horizontal b-scans improved in all patients. The 
regions identified by a semi-automated algorithm as cystoid spaces were outlined by 
a red contour. 
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Figure 3. Anatomical and visual effect of intravitreal aflibercept therapy in eight 
patients with macular telangiectasia type 1, over twelve months. 
(A) Mean central macular thickness. (B) Best-corrected visual acuity change (ETDRS 
letter score). All parameters were assessed at baseline, 1, 3, 6 and 12 months. The 
inferior and superior dotted lines indicate the standard deviation. Mean values were 
compared to baseline using a Wilcoxon paired test (*P<0.05; **P<0.01).  
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Figure 4.  Angiogenic factors profile in the aqueous humor determined by a 
multi-array high-sensitive immunoassay. VEGF-A, sFlt-1, PlGF, Tie-2, VEGF-D, 
VEGF-C and bFGF levels of male patients with macular telangiectasia type-1 (n=6, 
black dots) were compared to those of healthy age-matched male controls 
undergoing cataract extraction (n=8, white dots). The levels of Tie-2, VEGF-C and 
VEGF-D were below the detection threshold in some aqueous humor samples, 
explaining the lower number of represented values. Concentrations were compared 
between affected and control subjects using a Mann-Whitney U test. *P <.05; **P 
<.01; ns, not significant.  
 22 
 
 
 
Figure 5. Multimodal imaging in a 71-year-old male patient with macular 
telangiectasia type 1 affecting his left eye (Case 1). (A) Color fundus photograph 
showing telangiectasic microaneurysms and hard exudates. (B) Early-frame 
fluorescein angiogram (1 minute after dye injection) and (C) identification of the 
foveal avascular zone area on a 33-mm optical coherence tomography angiography 
image. (D) 33-mm optical coherence tomography angiography images of the 
superficial and (E) deep capillary plexus used to assess the corresponding capillary 
densities (F-G). The deep plexus shows pronounced capillary telangiectasis and 
microaneurysm formation in the inferotemporal macula.   
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SUPPLEMENTAL DATA 
 
  
 
Supplemental Figure. Semi-automated method to detect intraretinal cysts on 
optical coherence tomography. (A) Original horizontal B-scan spectral-domain 
optical coherence tomography through the fovea. (B) Detection of hyporeflective 
spaces by binary transformation. (C) Identification of boundaries of hyporeflective 
spaces, outlined in red. (D) Final image with cyst boundaries outlined in red, 
superimposed over the original B-scan. 
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 Angiogenic factors levels in aqueous humor (pg/mL) SD-OCT OCT angiography  
Eye sFlt-1 PlGF Tie-2 VEGF-A VEGF-C VEGF-D bFGF 
Baseline 
central 
macular 
thickness, µm 
 
Perifoveal 
density of 
superficial 
capillary plexus 
Perifoveal 
density of deep 
capillary plexus 
Foveal 
avascular zone 
area, mm
2
 
Baseline 
BCVA, 
ETDRS letter 
score 
(Snellen VA) 
1 418.05 3.79 22.41 12.16 5.03 U.D. 1.34 528 45.12 42.32 0.557 68 (~20/87) 
2 432.49 6.83 16.78 571.91 U.D. 3.74 11.37 394 43.4 45.94 0.42 95 (~20/25) 
3 353.38 8.60 25.98 100.86 20.95 1.79 2.23 348 38.61 39.04 1.098 48 (~20/220) 
4 179.16 2.19 10.75 241.11 14.46 U.D. 0.79 396 52.83 57.97 0.199 99 (~20/21) 
5 2890.88 2.39 29.94 11.47 12.49 15.01 6.33 595 50.6 48.49 0.603 83 (~20/44) 
6 261.27 3.16 6.60 186.33 U.D. U.D. 1.46 393 50.93 52.42 0.205 84 (~20/42) 
 
 
Supplemental Table1.docx 
Case-by-case values of angiogenic factor levels in aqueous humor, spectral-domain optical coherence tomography and 
optical coherence tomography angiography parameters, and visual acuity levels in six patients with macular 
telangiectasia type 1 who underwent aqueous humor tap. BCVA, Best-Corrected Visual Acuity; bFGF, basic Fibroblast Growth 
Factor; OCT, Optical Coherence Tomography; PlGF, Placental Growth Factor; SD-OCT, Spectral Domain OCT; sFlt1, soluble 
VEGF receptor 1; Tie-2, Tyrosine kinase with immunoglobulin-2 and EGF-like domains; U.D., Undetectable; VEGF, Vascular 
Endothelial Growth Factor 
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P-values (r) 
a
 SD-OCT OCT angiography 
 Baseline central 
macular 
thickness, µm 
 
Perifoveal 
density of 
superficial 
capillary plexus 
Perifoveal 
density of deep 
capillary plexus 
Foveal avascular 
zone area, mm
2
 
sFlt-1, pg/mL 0.4 0.4 0.4 0.2 
PIGF, pg/mL 0.2 0.03 (r = -0.89) 0.03 (r = -0.89) 0.2 
Tie-2, pg/mL 0.5 0.2 0.2 0.03 (r = 0.89) 
VEGF-A, pg/mL 0.4 0.6 0.6 0.2 
VEGF-C, pg/mL 0.3 0.9 0.9 0.8 
VEGF-D, pg/mL 0.3 0.3 0.3 1.0 
bFGF, pg/mL 0.9 0.5 0.5 0.4 
 
Supplemental Table2. Correlation between anatomical and biological 
parameters in six patients with macular telangiectasia type 1. bFGF= basic 
Fibroblast Growth Factor; OCT, Optical Coherence Tomography; PlGF, Placental 
Growth Factor; SD-OCT, Spectral Domain OCT; sFlt1= soluble VEGF receptor 1; 
Tie-2= Tyrosine kinase with immunoglobulin-2 and EGF-like domains; VEGF, 
Vascular Endothelial Growth Factor 
 
